Candel therapeutics reports first quarter 2023 financial results and recent corporate highlights

Needham, mass., may 11, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended march 31, 2023, and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking